#USA #Class Action #New Orleans #ClaimsFiler #ADMA Biologics

Urgent Notice for ADMA Biologics Investors

In the world of investment, timing can be everything, especially for those involved in securities class action lawsuits. For investors who suffered losses of more than $100,000 in ADMA Biologics, Inc. (NasdaqGM: ADMA), an important deadline approaches. ClaimsFiler, a service dedicated to helping shareholders, has announced that the deadline to file lead plaintiff applications is August 10, 2026. Understanding this lawsuit's implications can help you navigate your next steps.

Background of the Class Action Lawsuit

This lawsuit involves ADMA Biologics and certain company executives who are alleged to have failed in their duty to disclose critical information during the class period of August 9, 2024, to March 25, 2026. Such omissions have raised serious concerns about compliance with federal securities laws.

The specifics of the allegations include several troubling claims:

• - The company allegedly engaged in undisclosed related party transactions, which, if proven, undermine the transparency expected from publicly traded companies.
• - Another accusation points toward the practice of 'channel stuffing'—a technique used to inflate sales figures temporarily to create an illusion of robust revenue.
• - Furthermore, reports suggest that ADMA Biologics did not maintain adequate internal controls. This could indicate a systematic issue within the company's operations that warrants further scrutiny.

These allegations, if confirmed, suggest that ADMA's public statements regarding its business operations and outlook were not just misleading but materially inaccurate.

What the Lawsuit Means for You

For investors, the consequences of these allegations could be significant. If you have purchased ADMA securities during the specified class period, you have legal options available to reclaim your losses. The ongoing lawsuit poses an opportunity for affected shareholders to join in seeking accountability from the company and its executives.

By becoming a lead plaintiff, investors will have the ability to influence proceedings as the case unfolds. This can be pivotal for those looking to maximize the recovery potential stemming from any eventual settlement or verdict.

How to Take Action

For those interested in becoming lead plaintiffs, the process is fairly straightforward. Potential plaintiffs must register through ClaimsFiler, which serves as a free service for shareholders. Here are the steps you should consider:
1. Visit ClaimsFiler's Website: Go to ClaimsFiler.com to initiate your application.
2. Submit Your Information: Fill out the necessary forms detailing your ADMA investment and the losses incurred.
3. Engage with Legal Experts: ClaimsFiler can connect you with lawyers from Kahn Swick & Foti, LLC, who specialize in securities class actions. They can discuss your situation and explore your legal options.

Conclusion

As August 10, 2026, approaches, ADMA Biologics investors must act swiftly to protect their interests. The class action lawsuit against a prominent biotechnology firm sheds light on crucial issues related to corporate governance and transparency. Whether or not you decide to become a lead plaintiff, staying informed and understanding your rights as an investor is essential.

By taking the appropriate steps right now, you could potentially recover your losses and hold the company accountable for its actions.

Make sure you don't miss the deadline, and consult with legal experts to explore your options in this significant class action lawsuit. Act now, as time is of the essence.